±±¾©»ùÒò×éËù£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©½ÒʾÂí¶µÁåËáÍ»±äÌØÕ÷¿ÉÓÃÓÚʶ±ðÉÏÄò·Äò·ÉÏƤ°©µÍΣº¦ÑÇÐÍ
¡¡¡¡½üÈÕ£¬ÖпÆÔº±±¾©»ùÒò×éÑо¿Ëù£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©´ÈάÃôÑо¿×éÓë±±¾©´óѧµÚÒ»Ò½ÔºÖÜÀûȺ×éÏàÖú£¬½Òʾµ¥ºËÜÕËáÍ»±äÌØÕ÷µÄ·Ö×Ó·ÖÐͼ°Âí¶µÁåËá(AA)Ïà¹ØÍ»±äÌØÕ÷¿É×÷Ϊ·Ö×Ó±ê¼ÇÎïɸѡÉÏÄò·Äò·ÉÏƤ°©µÍΣº¦ÑÇÐͲ¢¾ßÓÐʵÏÖÎÞ´´¼ì²âµÄDZÁ¦£¬¸ÃÏîÑо¿½á¹ûÒÔ¡°Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma¡±ÎªÌâÔÚѧÊõÆÚ¿¯TheranosticsÔÚÏßÐû²¼¡£
¡¡¡¡Äò·ÉÏƤ°©ÊÇ×î³£¼ûµÄÃÚÄòϵͳ¶ñÐÔÖ×ÁöÖ®Ò»£¬ÆäÖÐԼĪ90%-95%µÄÄò·ÉÏƤ°©±¬·¢ÓÚ°òë×£¬ÉÏÄò·Äò·ÉÏƤ°©(UTUC)½öÕ¼5%-10%¡£µ«ÔÚ¶«ÑǵØÇø£¬ÓÉÓÚÖвÝÒ©µÄÁ÷ÐУ¬UTUCµÄÕ¼±È×î¸ßÁè¼Ý30%¡£ÓÐÑо¿ÒѾ֤ʵAA̻¶ÊÇUTUC¼°ÖвÝÒ©Éö²¡¸ß·¢µÄÖ÷ÒªÔÒò£¬±¾Ñо¿Ö¼ÔÚ̽Ë÷ÖйúUTUCµÄÁÙ´²·Ö×ÓÌØÕ÷¼°Ç±ÔÚµÄÕïÁÆ˼·¡£Ñо¿ÈËÔ±¶Ô90ÀýUTUCÑù±¾½øÐÐÈ«»ùÒò×é²âÐò£¬²¢Æ¾¾ÝÖ×ÁöÌåϸ°ûÍ»±äÊý¾Ý¿â£¨Catalogue of Somatic Mutations in Cancer£©ÒѽâÎöµÄÍ»±äÌØÕ÷¶ÔËùÓÐÑù±¾½øÐоÛÀàÆÊÎö£¬·¢Ã÷AAÍ»±äÌØÕ÷(signature 22)Õ¼±È¸ßµÄUTUC»¼Õß(¼´AA SigÑÇÀà)AAÖвÝҩ̻¶±ÈÀý½Ï¸ß£¬¸ÃÑÇ×éµÄÅ®ÐÔ»¼Õß±ÈÀý¸ß£¬³£ÌåÏֶಡÔîÒÔ¼°½Ï²îµÄÉö¹¦Ð§£¬µ«Éú´æÆÊÎö·¢Ã÷AA SigÑÇÀ໼ÕßÔ¤ºó½Ïsignature 22Õ¼±ÈµÍ(No-AA Sig)µÄ¸üºÃ¡£AA SigÑÇÀà¶àÔîÐÔ»¼ÕߵĶàÑù±¾»ùÒò×é¹ØÁªÆÊÎöÍƲ⣬ÇøÓò°©»¯ºÍ¹ÜÇ»ÖÖÖ²¿ÉÄÜÅäºÏÔö½ø¸ÃÑÇÀ໼ÕßµÄÖ×Áö¶à²¡ÔîºÍ°òë׸´·¢¡£±ðµÄ£¬AA SigÑÇÀàÖ×ÁöÌåÏÖ³ö½Ï¸ßµÄÍ»±ä¸ººÉ¡¢Ô¤²âÖ×Áö¿¹ÔÊýÁ¿ºÍÃâÒßϸ°û½þÈó£¬ÌåÏÖAA SigÑÇÀ໼Õß¿ÉÄÜÊÇÖ×ÁöÃâÒßÖÎÁƵÄDZÔÚÈËȺ¡£×îºó£¬¸ÃÑо¿·¢Ã÷ÀûÓõͲãÊýÈ«»ùÒò×é²âÐò£¬ÔÚÄòÒºÉÏÇåϸ°ûÓÎÀëDNA(cfDNA)ÖÐÈÔ¿ÉÔ¤²âAA SigÑÇÐÍ¡£ÉÏÊö½á¹û±êÃ÷AA SigÊÇÒ»ÀàµÍΣΣº¦Ö×ÁöÀàÐÍ£¬²¢ÓÐͨ¹ýÔÚÄòÒºÖнøÐÐÍ»±äÌØÕ÷¼ì²âʵÏÖÔçÆÚÕï¶ÏºÍ¼à²âµÄDZÁ¦¡£
¡¡¡¡¸ÃÑо¿»ñµÃÁËpgµç×Ó¹ÙÍøÕ½ÂÔÐÔÏȵ¼¿Æ¼¼×¨Ïî¡¢¹ú¼Ò×ÔÈ»¿ÆѧÒÔ¼°¹ú¼ÒÖصãÑз¢¼Æ»®µÈ»ù½ð×ÊÖú¡£
¡¡¡¡ÎÄÕÂÁ´½Ó
Âí¶µÁåËᣨAA£©Í»±äÌØÕ÷×÷ΪһÖÖɸѡ¹¤¾ß£¬Ê¶±ð¾ßÓÐÖÎÁÆÒâÒåµÄµÍΣº¦UTUCÑÇÀà